NATIONAL OSTEOPOROSIS FOUNDATION
NOF Press Release: Latest Findings About CalciumNOF-commissioned study published in this month's issue of ...
NOF-commissioned study published in this month's issue of Osteoporosis International finds no increased risk of cardiovascular disease from calcium supplement use. These findings also show that the long-term use of calcium and vitamin D supplements lower hip fracture risk in women.View Thread
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Reply: Prolia side effects for Glaucoma?After reviewing the prescription insert, medication guide and...
After reviewing the prescription insert, medication guide and approval history submitted to the FDA, we were unable to find any evidence suggesting a link between denosumab (Prolia) and the risk of glaucoma or increased intraocular pressure. Of course, always talk to your healthcare provider and pharmacist about your medical history, concerns and other prescriptions and over-the-counter medicines you take before starting a new treatment.View Thread
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Reply: Osteoprosis and gastric bypassHere's some information NOF has published for healthcare...
Here's some information NOF has published for healthcare professionals about bisphosphonate use in bariatric surgery patients. For the complete article visit http://www.nof.org/node/453 . If you've had bariatric surgery, you may want to share this information with your doctor.
"When osteoporosis is suspected in a bariatric surgery patient, secondary disease should be suspected first, and if present, should become the focus of treatment interventions. The etiology of the clinical presentation and biochemical indices such as vitamin D deficiency, hypocalcemia, elevated alkaline phosphatase, and secondary hyperparathyroidism should be clearly defined and appropriate treatment interventions initiated. Abnormal DXA may in fact be indicative of both primary and secondary disease however, aggressive treatment of the underlying cause of the secondary disease can result in significant improvements in BMD[34>. The addition of a bisphosphonate to the treatment regimen should only be considered after clinical and biochemical resolution of secondary metabolic bone disease (MBD).
Bisphosphonates inhibit bone resorption, slow calcium efflux from the skeleton and cause a compensatory rise in PTH. Administered in the presence of vitamin D deficiency such as that seen in our patient, normal serum calcium cannot be maintained despite dramatic increases in serum PTH, and life-threatening hypocalcemia can result[35-37>. Therefore, caution is advised when considering the use of oral bisphosphonates in this population due to the high prevalence of vitamin D deficiency and subclinical osteomalacia.
Oral bisphosphonate use in bariatric surgery patients should also be approached cautiously due to the lack of safety and efficacy data. Specifically, tolerance has not been established in the surgical gut, and risk of ulceration at surgical anastamosis has not been defined. Efficacy of oral bisphosphonates has also come into question following bariatric bypass procedures due to the high likelihood that the drug may not be adequately absorbed. It is for these reasons that if treatment for primary osteoporosis is indicated in a bariatric surgery patient, there should be no clinical or biochemical evidence of secondary bone disease, the patient should be taking daily calcium and vitamin D supplements, and intravenous bisphosphonates should be considered."View Thread
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Celebrate National Osteoporosis MonthCelebrate National Osteoporosis Month! NOF's Generations of Strength...
Celebrate National Osteoporosis Month! NOF's Generations of Strength Campaign encourages women and men to start conversations about bone health and family history as the first steps to protecting themselves and future generations from osteoporosis. In honor of National Osteoporosis Month, we hope you will join the conversation. To learn more, visit http://www.nof.org/toolkitView Thread
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Thanks for your Reply!
NATIONAL OSTEOPOROSIS FOUNDATION
Reply: ProliaDear Periwinkle — To answer your second question about why...
Dear Periwinkle — To answer your second question about why everyone is moved to another drug when they complete their two years of Forteo, this is because Forteo stops working almost immediately when you finish taking the medication. Many other osteoporosis medications stay in the body for a long time and can continue to work for a while, even when you stop taking them. This is not the case with Forteo. Many people experience substantial gains in bone density while on Forteo. If they don't switch to another drug, they can lose these gains fairly quickly. Unfortunately, these losses increase a person's risk of breaking a bone.
I hope this helps answer your question!View Thread
Thanks for your Reply!
